OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Show more...
FAQ
OKYO Pharma Limited 今天的股价是多少?▼
OKYO.LSE 当前价格为 £1.40 GBP,在过去 24 小时内下跌了 -24.32%。在图表上更密切关注 OKYO Pharma Limited 股票的表现。
OKYO Pharma Limited 的股票代码是什么?▼
根据交易所不同,股票代码可能会有所不同。例如,在 London Exchange 交易所,OKYO Pharma Limited 的股票以代码 OKYO.LSE 进行交易。
OKYO Pharma Limited 有多少名员工?▼
截至九月 06, 2026,公司共有7名员工。
OKYO Pharma Limited 属于哪个行业?▼
OKYO Pharma Limited从事于健康与养生行业。
OKYO Pharma Limited 何时完成拆股?▼
OKYO Pharma Limited 最近没有进行任何拆股。
OKYO Pharma Limited 的总部在哪里?▼
OKYO Pharma Limited 的总部位于 其他 的 London。